Adocia SAS (ADOC.PA) Stock Performance
Adocia SAS, the French clinical‑stage biotechnology firm focused on therapeutic protein formulations, experienced a notable 7.83 % rise in its share price over a 24‑hour period ending at 05:33 AM Central Europe on Thursday, 22 nd. At the time of reporting, the stock trades at approximately EUR 2.36 on major exchanges. The company’s current supply of shares stands at 19.9 million, translating into a market capitalization of EUR 47.4 million.
Trading Activity
In the past 24 hours, roughly EUR 1.3 million worth of Adocia SAS shares changed hands. Over the preceding month, the stock has fallen 31.6 %, reflecting broader market sentiment and perhaps investor caution regarding its clinical pipeline. The 200‑day simple moving average is positioned at EUR 4.65, indicating that the current price lies below a key trend‑support level. Historical extremes show a 52‑week high of EUR 9.76 (recorded on 10 29 2025) and a low of EUR 2.01 (on 10 08 2026), underscoring a pronounced price volatility over the past year.
Peer Performance Snapshot
For context, the performance of related stocks in the same 24‑hour window was mixed:
| Stock | Ticker | 24‑hour change | Current price | Market cap | P/E ratio |
|---|---|---|---|---|---|
| Groupe Ldlc | ALLDL.PA | -2.27 % | EUR 8.7 | EUR 53.1 mn | 5.27 |
| Saint Jean Groupe | SABE.PA | 0 % | EUR 16.9 | EUR 56.3 mn | – |
| Hotelim | MLHOT.PA | 0 % | EUR 53.5 | EUR 51.9 mn | 50.45 |
| Hydraulique | MLHYD.PA | 0 % | EUR 720 | EUR 50.2 mn | 7.38 |
| Hoffmann Green Cement Techno | ALHGR.PA | +0.31 % | EUR 3.28 | EUR 53.4 mn | – |
The varied movements illustrate differing investor sentiment across sectors, with Adocia’s upward movement standing out amid a generally stagnant or modestly negative market backdrop.
Company Overview
Adocia SAS is headquartered in Lyon, France, and specializes in developing formulations of pre‑approved therapeutic proteins and peptides for metabolic diseases such as diabetes. Its proprietary BioChaperone platform incorporates novel polymers, oligomers, and small molecules designed to enhance the efficacy and safety of therapeutic proteins.
Key products in the clinical pipeline include:
- Ultra‑rapid insulin analogues (BioChaperone Lispro U100/U200)
- Rapid‑acting human insulin (HinsBet U100)
- Basal/rapid insulin combinations (BioChaperone Combo)
- Prandial human insulin with amylin pramlintide (BioChaperone Pramlintide Insulin)
- Aqueous human glucagon formulations (BioChaperone Human Glucagon)
The company is also advancing combinations with GLP‑1 and GLP‑2 analogues, such as BioChaperone Glargine Dulaglutide, Liraglutide, Teduglutide, and a glucagon‑GLP‑1 dual agonist for obesity treatment.
Founded in 2005, Adocia maintains a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. The firm is listed on the NYSE Euronext Paris exchange and maintains its website at www.adocia.com .
